learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Search
forLearn
5 / 801 resultslearn ACETYL TETRAPEPTIDE-2
learn phosphorus
learn octapeptide-2
learn acetyl tetrapeptide-3
Research
5 / 1000+ results
research Live imaging of Smad2/3 signaling in mouse skin wound healing
Smad2/3-dependent TGF-β signaling increases during wound healing.
research Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma
Lower SMAD2/3 activation predicts more severe skin cancer.
research Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
Kaempferol promotes hair growth and could be a natural treatment for hair loss.
research From hair to liver: emerging application of hair follicle mesenchymal stem cell transplantation reverses liver cirrhosis by blocking the TGF-β/Smad signaling pathway to inhibit pathological HSC activation
Hair follicle stem cell transplants can reverse liver cirrhosis by blocking harmful cell activation.
research Mir-574-3p and Mir-125a-5p in Adipose Derived Mesenchymal Stem Cell Exosomes Synergistically Target TGF-β1/Smad2 Signaling Pathway for the Treatment of Androgenic Alopecia
Two microRNAs in stem cell exosomes help treat hair loss by targeting a specific signaling pathway.
Community Join
5 / 1000+ resultscommunity My understanding of how androgenetic alopecia works (plus FIN and DUT)
Androgenetic alopecia is affected by scalp DHT levels, not sensitivity, with treatments like finasteride and dutasteride aiming to optimize these levels. Personalized DHT management is crucial for effective hair growth.
community Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.